Foreign Price Controls on Medicines Are a Step in the Wrong Direction
Price Controls Hurt American Patients
Price controls threaten to undermine the innovation ecosystem that has made the United States a global leader in medical advancements.
The U.S. Chamber of Commerce is leading the charge against harmful price control policies.
Our research reveals that such policies deter investment in life-saving treatments, delay patient access to new medicines, and jeopardize the development of groundbreaking cures for chronic and life-threatening diseases. We are committed to protecting American patients and ensuring they continue to benefit from the world’s most advanced and accessible healthcare innovations.
Stay Informed
Want to stay informed on how most-favored nation price controls on medicines affect your community? Sign up for our newsletter.
The MFN Trap: Copycat Price Controls Threaten Tomorrow's Cures
MFN pricing undermines innovation, delays treatments, and threatens economic growth.
What You Need to Know About Foreign Price Controls
- Fact:Patients in countries with price controls must often wait up to 500 days before they can receive the treatment they need.Read More
- Fact:Most-Favored Nation (MFN) pricing risks undermining the U.S. economy by jeopardizing up to 2.2 million high-skilled, high-paying jobs in the biopharmaceutical sector and its supply chain.Read More
- Fact:MFN pricing could reduce U.S. life sciences R&D spending by 18.5% and cut clinical trial activity by up to 75%.Read More
- Most-Favored Nation (MFN) pricing threatens the U.S.'s leadership in biopharmaceutical innovation by disincentivizing investment in research and development, which is critical for discovering new treatments and cures.
- Importing foreign price controls into the U.S. healthcare system undermines the innovation ecosystem, delaying access to life-saving medicines and jeopardizing future medical breakthroughs.
- Instead of adopting harmful price control policies, the U.S. should focus on market-driven solutions that lower costs while preserving the incentives that drive medical innovation and protect patient access.
Learn More
Latest Content
- With price controls, patients will have fewer cures, longer wait times, and diminished hope for the future.MFN pricing undermines innovation, delays treatments, and threatens economic growth.Powerful polling shows market-based solutions are essential to protect patient access, encourage innovation, and maintain U.S. leadership in life sciences.Explore the impact on life-saving treatments, research funding, and patient access, and discover market-driven solutions to ensure continued healthcare advancements for American patients.U.S. Chamber of Commerce Senior Vice President for Economic Policy, Tom Quaadman, issued the following statement on the administration's EO involving drug pricing.Introducing MFN pricing would impose harmful price controls that undermine U.S. investment in the next generation of breakthrough medicines.U.S. Chamber of Commerce Senior Vice President, Global Innovation Policy Center (GIPC), Brad Watts, issued the following statement after President Trump signed an executive order aimed at lowering drug prices.Strong IP incentives have been instrumental in bringing groundbreaking treatments to market, offering hope and improved quality of life to millions of patients.Government price setting jeopardizes our medical innovation leadership and limits patient access to cutting-edge treatments.
